Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Glioblastoma Genomics: A Very Complicated Story

Melanie Y. Lombardi  1 , Mahfoud Assem  2
Steven De Vleeschouwer  1
, editors.
In: Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 1.
Affiliations
Free Books & Documents
Review

Glioblastoma Genomics: A Very Complicated Story

Melanie Y. Lombardi et al.
Free Books & Documents

Excerpt

Glioblastoma is a deadly disease that has not shown improvement despite the development of new diagnostic tools and innovative targeted therapies. This grim outcome is mainly related to a complex intra- and inter-individual heterogeneity resulting from severe genetic instability. Understanding glioblastoma biology may establish a foundation to improve prophylaxis, early diagnosis, prognosis, and treatment prediction, thus leading to a better outcome. Recent advances in technologies such as genomics, epigenomics, transcriptomics, and proteomics have led to unprecedented discoveries of potential prognostic and predictive markers. Several of these biomarkers are in deep need of validation to be used in clinical routine. In this chapter, we will discuss the most accomplished recent advances in the genomics of glioblastoma and insight into personalized medicine using validated, and not yet validated, biomarkers that may have great potential to improve patients’ outcomes.

PubMed Disclaimer

References

    1. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2006;20(4):E1. doi: 10.3171/foc.2006.20.4.E1. - DOI - PubMed
    1. Reardon DA, Herndon JE, 2nd, Peters KB, Desjardins A, Coan A, Lou E, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer. 2012;107(9):1481–7. doi: 10.1038/bjc.2012.415. - DOI - PMC - PubMed
    1. Loeb LA. Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer. 2011;11:450–7. doi: 10.1038/nrc3063. - DOI - PMC - PubMed
    1. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103:1139–43. doi: 10.1038/sj.bjc.6605912. - DOI - PMC - PubMed
    1. Assem M, Sibenaller Z, Agarwal S, Al-Keilani MS, Alqudah MAY, Ryken TC. Enhancing diagnosis, prognosis and therapeutic outcome prediction of gliomas using genomics. OMICS. 2012;16(3):113–22. doi: 10.1089/omi.2011.0031. - DOI - PMC - PubMed

LinkOut - more resources